Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer

This is the authors' abstract. We don't add key points for this paper.

Bifunctional agents that simultaneously antagonize and degrade various AR proteins more effectively block the AR signaling pathway, offering a promising strategy for the treatment of mCRPC patients. Herein, we report the discovery and development of a series of small-molecule AR degraders with 3,8-diazabicyclo[3.2.1]octan scaffold. The optimal compound 20i exhibited potent AR antagonistic and degrading activities, effectively overcoming multiple resistance mechanisms and showing significant antiproliferative effects against enzalutamide-resistant PCa cell lines. Moreover, compound 20i exhibited favorable oral pharmacokinetics and a good safety profile. In the 22Rv1 xenograft models, 20i exhibited potent antitumor activity without obvious toxicity. Taken together, these results demonstrated that 20i might be a potential candidate for the treatment of enzalutamide-resistant PCa.